FDA approves brepocitinib as first oral drug for adult dermatomyositis

What happened

The Food and Drug Administration on August 27 approved Lisraya, or brepocitinib, for adults with dermatomyositis, making it the first FDA-approved oral treatment specifically indicated for the rare autoimmune disease.

Dermatomyositis can produce progressive muscle weakness, inflammatory skin disease and impairment across multiple organ systems. Treatment has often involved glucocorticoids and other immune-modulating drugs used off label. The new approval establishes a regulated oral option, but it does not eliminate the need to weigh immunosuppressive risks or show how the medicine performs beyond the population studied.

Brepocitinib inhibits TYK2 and JAK1, signaling enzymes involved in inflammatory cytokine pathways. FDA granted the application Priority Review and Orphan Drug designations. Priovant Therapeutics received the approval.

The trial behind the decision

The principal evidence came from VALOR, a sponsor-funded phase 3 trial whose primary results were published online in the New England Journal of Medicine on March 28, 2026. The FDA decision therefore is new; the underlying efficacy publication is not.

Investigators enrolled 241 adults whose dermatomyositis had been resistant to previous therapy. Participants were randomly assigned, under double-blind conditions, to receive one of two brepocitinib doses or placebo for 52 weeks. Background standard therapies continued, while glucocorticoids were tapered.

The primary endpoint was the Total Improvement Score at week 52. This validated composite ranges from zero to 100 and combines changes in muscle strength, physical function, muscle enzymes, skin and other disease activity, plus physician and patient assessments.

The mean score was 46.5 in the 30-milligram group, 37.5 in the 15-milligram group and 31.2 with placebo. The difference between the higher dose and placebo was 15.3 points, with a 95% confidence interval from 6.7 to 24.0. The lower dose did not produce a statistically significant difference from placebo.

The higher-dose group also performed better across the trial’s nine multiplicity-controlled secondary endpoints, including skin activity, functional disability and glucocorticoid reduction. Those outcomes support a broader clinical effect than a change in a laboratory marker alone.

Safety limits the headline

Serious infections occurred in 10% of participants receiving the higher dose and 1% of those receiving placebo. No deaths occurred during the trial. FDA listed upper respiratory infections, headache, fatigue, urinary tract infections and nausea among the most common adverse reactions.

Lisraya carries a boxed warning covering serious infections, malignancies, major cardiovascular events, thrombosis and increased all-cause mortality. Some warning components reflect safety concerns associated with the JAK-inhibitor class and cannot be fully characterized by a 241-person, one-year trial. Rare harms, longer-term risks and outcomes in people unlike the enrolled population require continued surveillance.

What the evidence means

This is evidence of improvement in a composite disease-activity measure, physical function, skin disease and steroid tapering among adults with previously treated dermatomyositis. It is not evidence that the drug cures the disease, prevents every complication or is safer for every patient than existing approaches.

The randomized, placebo-controlled design, prespecified endpoints, peer-reviewed publication and FDA review make the efficacy finding comparatively strong. Important uncertainties remain because the evidence centers on one sponsor-funded phase 3 trial, follow-up lasted 52 weeks and only the higher tested dose demonstrated significant benefit on the primary endpoint.

The practical advance is narrower but still consequential: adults with dermatomyositis now have an approved oral treatment backed by controlled human evidence. How the therapy compares directly with other immune-modulating strategies, and how its benefits and risks hold up over years, remain open questions.